Piper Sandler on Skye Bioscience (SKYE): 'Own for Upcoming Phase II CBeyond Data on Nimacimab'
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $20.00 price target on Skye Bioscience (NASDAQ: SKYE).The analyst commeneted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
